When you use an inhaler, you might assume the white powder delivering your medication is simply the drug itself. In reality, that powder contains a carrier that helps the medicine reach deep into your lungs. For decades, lactose has dominated this role, accounting for the vast majority of dry powder inhaler formulations. However, lactose has significant limitations that researchers are now addressing with natural alternatives. Polysaccharides extracted from plants are emerging as superior carriers, offering enhanced targeting, better safety profiles, and improved therapeutic outcomes for respiratory diseases.
The Lactose Problem
Lactose became the standard carrier for inhaled drugs largely by default. Regulatory agencies approved it early because of existing toxicological data, not necessarily because it was optimal (Hebbink et al., 2022). The majority of commercially available dry powder inhaler formulations rely on lactose because alternatives lacked sufficient safety documentation.
The problem with lactose extends beyond simple convenience. Its reducing sugar function makes it chemically incompatible with proteins and peptides, causing degradation through reactions that compromise drug stability (Mansour et al., 2009). This limitation becomes critical as pharmaceutical development increasingly focuses on biological therapies, including protein-based drugs and vaccines delivered via inhalation.
Lactose carrier particles in conventional dry powder inhalers act primarily as inert diluents and dispersion aids and, as such, provide essentially no specific mucoadhesion to prolong drug residence in the lungs, no active targeting mechanisms for particular pulmonary cell types, and no intrinsic capacity to confer controlled or sustained drug release (Smyth & Hickey, 2005). Essentially, lactose serves as an inert vehicle when modern medicine demands carriers that actively contribute to therapeutic efficacy.
Enter Natural Polymers
Polysaccharides extracted from natural sources offer distinct advantages over synthetic materials in pharmaceutical applications (Idrees et al., 2020). These naturally derived polymers demonstrate superior biocompatibility, are available at large scale, and provide functional properties that enable cell targeting through receptor recognition and site-specific enzymatic degradation (Barclay et al., 2019).
Locust bean gum (LBG), a galactomannan extracted from carob tree seeds, exemplifies this new generation of carriers. Research has established that LBG microparticles achieve aerodynamic diameters of 4.6 micrometers with fine particle fractions around 29%, matching the performance of marketed inhaler products (Pinto da Silva et al., 2025). These particles demonstrate superior mucoadhesive properties compared to lactose, with adhesion forces comparable to chitosan, a polymer known for its mucoadhesive capacity (Pinto da Silva et al., 2025).
The mannose and galactose residues within the LBG structure likely enable recognition by mannose receptors on immune cells. Flow cytometry studies reveal that 70 to 90% of macrophages successfully internalize LBG microparticles (Pinto da Silva et al., 2025). This targeted delivery to immune cells makes LBG particularly valuable for vaccine applications.
Chitosan and Beyond
Chitosan, derived from crustacean shells, represents another natural polymer with proven pulmonary delivery potential. Its positive charge at physiological pH enables strong electrostatic interactions with the negatively charged mucus layer, extending drug residence time in the respiratory tract (Shim & Yoo, 2020). Chitosan nanoparticles demonstrate effective mucoadhesion while maintaining biocompatibility across multiple cell models.
Other natural gums under investigation include guar gum and xanthan gum. These polysaccharides share common advantages, including gelling properties, controlled swelling behavior, and the capacity for sustained release (Petitjean & Isasi, 2022). Their swelling characteristics prove particularly valuable, as particles can transform after lung deposition to evade rapid clearance mechanisms.
The challenge with natural polymers involves variability. These materials vary in molecular weight and chemical composition depending on source and extraction method, which can complicate achieving consistent pharmaceutical performance (Idrees et al., 2020). Addressing this requires rigorous purification protocols and comprehensive characterization before clinical use.
From Research to Reality
Translating natural polymer research into approved therapies requires extensive safety validation. Recent studies have performed comprehensive cytocompatibility evaluations across multiple relevant cell models, including alveolar epithelium, bronchial epithelium, and three-dimensional airway tissue constructs (Pinto da Silva et al., 2025). These assessments demonstrate that LBG microparticles maintain cell viability above 70% at physiologically relevant concentrations, with minimal membrane damage and negligible oxidative stress.
Animal studies provide additional validation. Research in rodent models shows that inhaled LBG microparticles loaded with bacterial antigens generate significant mucosal antibody responses without systemic toxicity, as evidenced by normal weight gain and blood cell counts within physiological ranges (Pinto da Silva et al., 2025). These findings support the continued development of natural polymer carriers for respiratory immunization.
The regulatory pathway for new excipients remains challenging. Agencies require extensive documentation of safety, manufacturing consistency, and functional performance. However, the increasing limitations of lactose-based formulations, combined with the expanding pipeline of biological therapeutics requiring pulmonary delivery, create strong incentives for developing approved natural polymer alternatives.
The Path Forward
Natural polysaccharides represent more than simple lactose replacements. They offer functional advantages, including cell targeting, mucoadhesion, and compatibility with sensitive biological drugs. While challenges in standardization and regulatory approval remain, the scientific foundation supporting these materials continues to strengthen. As research progresses from laboratory characterization through preclinical validation, natural polymers are positioned to become standard components of next-generation inhaled therapies, particularly for vaccines and protein-based treatments where lactose proves inadequate.
Discussion